UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000049482 |
|---|---|
| Receipt number | R000056332 |
| Scientific Title | A scoping review of Acquired Von Willebrand syndrome in ECMO patients |
| Date of disclosure of the study information | 2022/11/13 |
| Last modified on | 2024/11/13 12:49:38 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A scoping review of Acquired Von Willebrand syndrome in ECMO patients
Acronym
A scoping review of Acquired Von Willebrand syndrome in ECMO patients
Scientific Title
A scoping review of Acquired Von Willebrand syndrome in ECMO patients
Scientific Title:Acronym
A scoping review of Acquired Von Willebrand syndrome in ECMO patients
Region
| Japan |
Condition
Condition
Acquired Von Willebrand syndrome
Classification by specialty
| Hematology and clinical oncology | Vascular surgery | Cardiovascular surgery |
| Emergency medicine | Intensive care medicine |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
The purpose of this scoping review is to organize current knowledge of Acquired Von Willebrand syndrome in ECMO patients.
Basic objectives2
Others
Basic objectives -Others
The aim of this scoping review is to identify current knowledge of epidemiology, pathophysiology, testing, diagnostic methods, and treatment of acquired Von Willebrand syndrome in ECMO patients.
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Epidemiology, pathophysiology, testing, diagnostic methods, and treatment of acquired Von Willebrand syndrome in ECMO patients.
Key secondary outcomes
Base
Study type
Others,meta-analysis etc
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Literature review
1)Acquired Von Willebrand syndrome in ECMO patients.
2)Original articles written in English.
Key exclusion criteria
1)Review
2)Editor
3)Commentary
4)Conference abstract
Target sample size
Research contact person
Name of lead principal investigator
| 1st name | Yu |
| Middle name | |
| Last name | Amemiya |
Organization
Osaka medical and pharmaceutical university
Division name
Department of Emergency and Critical Care Medicine
Zip code
5698686
Address
Daigaku-machi, 2-7, Takatsuki, Osaka
TEL
072-683-1221
yu.amemiya@ompu.ac.jp
Public contact
Name of contact person
| 1st name | Yu |
| Middle name | |
| Last name | Amemiya |
Organization
Osaka medical and pharmaceutical university
Division name
Department of Emergency and Critical Care Medicine
Zip code
5698686
Address
Daigaku-machi, 2-7, Takatsuki, Osaka
TEL
072-683-1221
Homepage URL
yu.amemiya@ompu.ac.jp
Sponsor or person
Institute
Osaka medical and pharmaceutical university
Institute
Department
Personal name
Funding Source
Organization
Osaka medical and pharmaceutical university
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Osaka medical and pharmaceutical university
Address
Daigaku-machi, 2-7, Takatsuki, Osaka
Tel
072-683-1221
yu.amemiya@ompu.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2022 | Year | 11 | Month | 13 | Day |
Related information
URL releasing protocol
none
Publication of results
Unpublished
Result
URL related to results and publications
none
Number of participants that the trial has enrolled
0
Results
A total of 1639 articles were waded through the database.
Forty-one articles were extracted through screening.
Results date posted
| 2024 | Year | 11 | Month | 13 | Day |
Results Delayed
| Delay expected |
Results Delay Reason
Full-text screening is time-consuming.
Date of the first journal publication of results
Baseline Characteristics
A total of 1639 articles were waded through the database.
Forty-one articles were extracted through screening.
Participant flow
A total of 1639 articles were waded through the database.
Forty-one articles were extracted through screening.
Adverse events
none
Outcome measures
none
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
No longer recruiting
Date of protocol fixation
| 2022 | Year | 11 | Month | 10 | Day |
Date of IRB
| 2022 | Year | 11 | Month | 10 | Day |
Anticipated trial start date
| 2022 | Year | 11 | Month | 10 | Day |
Last follow-up date
| 2023 | Year | 06 | Month | 30 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
A systematic search will be conducted using the following databases and search terms, and three independent reviewers will be conducted a screening and extracted data. Arbitration will be conducted by a third reviewer as needed.
[Databases]
PubMed, scopus, cochrane reviews
[Search words]
"Extracoporeal membrane oxygenation"
"Von Willebrand syndrome", etc.
Patients
Acquired von Willebrand syndrome (AVWS) patient under (or after) veno-venous or veno-arterial extracorporeal membrane oxygenation. They receive any treatment.
Concept
We will review the existing literature on the etiology, laboratory test, diagnosis, treatment and prognosis of ACWS.
Context
we will not limit the context to cultural factors such as geographic location, specific racial or gender or age or particular settings such as acute care, primary health care or the community.
We will not limit the context to cultural factors such as geographic location, specific racial or gender or particular settings such as acute care, primary health care or the community.
Management information
Registered date
| 2022 | Year | 11 | Month | 12 | Day |
Last modified on
| 2024 | Year | 11 | Month | 13 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000056332
